US Stock MarketDetailed Quotes
KRBP Kiromic BioPharma
- 3.077
- -0.004-0.11%
15min DelayTrading May 17 12:18 ET
3.96MMarket Cap-414P/E (TTM)
3.077High3.077Low206Volume3.077Open3.080Pre Close633.76Turnover0.02%Turnover RatioLossP/E (Static)1.29MShares5.49052wk High-0.55P/B3.53MFloat Cap0.16052wk Low--Dividend TTM1.15MShs Float555.000Historical High--Div YieldTTM0.00%Amplitude0.160Historical Low3.076Avg Price1Lot Size
Kiromic BioPharma Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -38.09%-5.7M | 10.61%-21.23M | -31.80%-5.41M | 14.21%-5.23M | -8.25%-6.46M | 45.55%-4.13M | -16.85%-23.75M | 55.24%-4.1M | -26.67%-6.1M | -60.97%-5.97M |
| Net income from continuing operations | -16.00%-6.15M | 39.68%-20.95M | 33.63%-4.69M | 64.64%-4.19M | 19.80%-6.76M | 28.07%-5.3M | -35.73%-34.73M | 33.54%-7.07M | -93.65%-11.86M | -69.57%-8.44M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | 87.90%-12.8K | ---- | ---- | ---- |
| Depreciation and amortization | 0.18%557K | 32.73%2.22M | 0.13%555.6K | 4.38%560.1K | 37.66%549.4K | 204.16%556K | 256.19%1.67M | 306.82%554.9K | 309.62%536.6K | 273.69%399.1K |
| Other non cash items | -26.67%154K | -84.54%574.8K | -95.64%150.3K | -322.57%-297.8K | 4,674.11%512.3K | 39.63%210K | --3.72M | --3.44M | --133.8K | ---11.2K |
| Change In working capital | -182.86%-319K | -173.53%-3.21M | 9.20%-1.48M | -127.99%-1.32M | -141.87%-792.9K | 161.66%385K | 515.22%4.37M | -454.77%-1.63M | 6,101.05%4.73M | 1,832.66%1.89M |
| -Change in receivables | ---- | --0 | --0 | --0 | ---- | ---- | 65.31%16.2K | --0 | --0 | --0 |
| -Change in prepaid assets | -58.95%-666K | -127.07%-179.3K | -50.31%332.2K | 346.47%450.8K | -736.93%-543.3K | -557.92%-419K | 159.28%662.4K | 170.45%668.5K | 42.84%-182.9K | 12.09%85.3K |
| -Change in payables and accrued expense | -47.15%501K | -160.07%-2.45M | 23.75%-1.66M | -132.25%-1.63M | -105.83%-104.8K | 260.95%948K | 124.08%4.07M | -253.67%-2.18M | 1,241.66%5.05M | 1,069.31%1.8M |
| -Change in other current liabilities | -6.94%-154K | -53.53%-586.8K | -26.52%-150.3K | -12.15%-147.7K | -956.80%-144.8K | 3.10%-144K | ---382.2K | ---118.8K | ---131.7K | --16.9K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -38.06%-5.7M | 10.61%-21.23M | -31.80%-5.41M | 14.21%-5.23M | -8.24%-6.46M | 45.53%-4.13M | -16.85%-23.75M | 55.24%-4.1M | -26.67%-6.1M | -60.97%-5.97M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -21K | 95.75%-206.6K | -158.53%-109.1K | -173.64%-97.5K | 0 | 0 | -168.69%-4.87M | 96.15%-42.2K | 207.73%132.4K | -352.94%-2.47M |
| Capital expenditure reported | ---- | 95.77%-206.6K | ---- | ---- | ---- | ---- | ---4.88M | ---- | ---- | ---- |
| Net PPE purchase and sale | ---21K | --0 | -97.98%97.5K | -173.64%-97.5K | --0 | --0 | 100.79%15K | 540.93%4.84M | 163.99%132.4K | -352.94%-2.47M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---21K | 95.75%-206.6K | -158.53%-109.1K | -173.64%-97.5K | --0 | --0 | -168.69%-4.87M | 96.15%-42.2K | 207.73%132.4K | -352.94%-2.47M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 11.83%6.19M | 514.72%23.99M | -0.37%4.34M | 6,193.99%7M | 4,263.23%7.11M | 3,380.21%5.54M | -89.55%3.9M | 858.47%4.36M | -100.31%-114.9K | -1,481.48%-170.8K |
| Net issuance payments of debt | 6.08%6.19M | 471.40%23.44M | -4.71%4.34M | 6,218.28%7.03M | 3,749.53%6.23M | 3,557.94%5.84M | 4,349.78%4.1M | 902.46%4.56M | -25.44%-114.9K | -25.40%-170.8K |
| Net common stock issuance | ---- | --659.1K | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- |
| Net other financing activities | ---- | 44.40%-111.2K | ---1.6K | ---27.9K | --218.3K | ---300K | 93.06%-200K | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 11.83%6.19M | 514.72%23.99M | -0.37%4.34M | 6,193.99%7M | 4,263.23%7.11M | 3,380.21%5.54M | -89.55%3.9M | 858.47%4.36M | -100.31%-114.9K | -1,481.48%-170.8K |
| Net cash flow | ||||||||||
| Beginning cash position | 396.74%3.2M | -97.46%645.2K | 912.13%4.38M | -58.46%2.7M | -86.42%2.05M | -97.46%645K | 149.78%25.35M | -98.77%432.7K | 112.04%6.51M | 106.17%15.12M |
| Current changes in cash | -66.50%472K | 110.36%2.56M | -653.18%-1.18M | 127.56%1.68M | 107.55%650K | 113.77%1.41M | -262.52%-24.71M | 102.17%212.5K | -118.94%-6.08M | -101.94%-8.61M |
| End cash Position | 78.97%3.68M | 396.59%3.2M | 396.59%3.2M | 912.13%4.38M | -58.46%2.7M | -86.42%2.05M | -97.46%645.2K | -97.46%645.2K | -98.77%432.7K | 112.04%6.51M |
| Free cash flow | -38.57%-5.72M | 25.13%-21.43M | -32.62%-5.52M | 10.67%-5.33M | 23.47%-6.46M | 58.97%-4.13M | -28.85%-28.63M | 59.47%-4.16M | -18.81%-5.96M | -98.44%-8.44M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
